BiotechTube

Quizartinib

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Impairment

Conditions

Hepatic Impairment

Trial Timeline

Sep 30, 2024 → Mar 1, 2026

NCT ID
NCT06740799

About Quizartinib

Quizartinib is a phase 1 stage product being developed by Daiichi Sankyo for Hepatic Impairment. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06740799. Target conditions include Hepatic Impairment.

What happened to similar drugs?

3 of 18 similar drugs in Hepatic Impairment were approved

Approved (3) Terminated (5) Active (12)
✅RifaximinBausch HealthApproved
✅Placebo + RifaximinBausch HealthApproved
✅Rifaximin + LactuloseBausch HealthApproved
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄PhosphatidylcholineSanofiPhase 3
❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3
🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT06772246Phase 1Completed
NCT06740799Phase 1Recruiting
NCT04473664Phase 1Completed
NCT03723681Phase 1Completed
NCT02984995Phase 2Completed

Competing Products

20 competing products in Hepatic Impairment

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
19
GB1211 + PlaceboComac MedicalPhase 1/2
18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
23
OlomorasibEli LillyPhase 1
29
SimufilamCassava SciencesPhase 1
19
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
DS-3201bDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
29
PexidartinibDaiichi SankyoPhase 1
29
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
29
BocidelparAstellas PharmaPhase 1
29
fezolinetantAstellas PharmaPhase 1
29
enzalutamideAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP2215Astellas PharmaPhase 1
29
BPN14770ShionogiPhase 1
29
S-217622ShionogiPhase 1
29
LemborexantEisaiPhase 1
29
LenvatinibEisaiPhase 1
29